Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Certolizumab pegol
Cimzia
Routinely available
NICE (TA383 (SMC 960/14))
29/03/2023
Indication
For the treatment of adult patients with severe active axial spondyloarthritis.
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
200mg/mL solution for injection in pre-filled syringe
Comments
March 23 - ERF status update - refer to pathway Treatment of Axial Spondyloarthritis in pregnancy.
Link to Advice
Advice Published
01/02/2016